Biodesix Teaming With Biognosys to Apply DIA Mass Spec to Companion Dx Development | GenomeWeb

NEW YORK(GenomeWeb) – Diagnostics firm Biodesix said this week that it is collaborating with Swiss proteomics firm Biognosys on companion diagnostic development.

The collaboration will use Biognosys' HRM mass spec technology to complement Biodesix's traditional MALDI-TOF approach to biomarker discovery and development, Paul Beresford, Biodesix's chief business officer, told GenomeWeb.

Specifically, the company aims to better understand the specific analytes underlying the MALDI-TOF mass spec signal comprising its tests, Beresford said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.